Eli Lilly and Company
1,124.21USD
+0.2999 (+0.03%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22,974 | 19,799 | 19,292 | 17,601 | 15,558 | 12,729 | 13,533 | 11,439 |
| Cost of Revenue | 3,268 | 3,577 | 3,372 | 3,008 | 2,448 | 2,225 | 2,404 | 2,171 |
| Gross Profit | 19,706 | 16,222 | 15,920 | 14,593 | 13,110 | 10,504 | 11,130 | 9,268 |
| Operating Income | — | — | — | — | — | — | — | — |
| Net Income | 7,095 | 7,396 | 6,638 | 5,583 | 5,661 | 2,759 | 4,410 | 970 |
| EPS (Diluted) | $7.94 | $8.26 | $7.39 | $6.21 | $6.29 | $3.06 | $4.88 | $1.07 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)